Payment overview · 2025
General Payments
$208.67
11 reported records · 6 companies
Healthcare provider profile · identity verified
Ariel Benjamin Vazquez
Allopathic & Osteopathic Physicians|Internal Medicine · MIAMI, FL · NPI 1407351372
Verified facts
What the public records show
CMS Open Payments records show Ariel Benjamin Vazquez received $208.67 in general payments during 2025 across 11 reported records.
Amgen Inc. accounted for 37.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Shingrix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $78.27 | 37.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.42 | 19.9% | 2 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $36.66 | 17.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.94 | 9.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.02 | 8.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.36 | 7.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $208.67 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $78.27 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $38.45 | 2 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $36.66 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 116 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
116 | 78 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 828 | 292 |
| Losartan Potassium | Losartan Potassium | 451 | 144 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 369 | 117 |
| Lisinopril | Lisinopril | 331 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 313 | 117 |
| Gabapentin | Gabapentin | 295 | 86 |
| Metformin Hcl | Metformin Hcl | 293 | 102 |
| Fluticasone Propionate | Fluticasone Propionate | 263 | 120 |
| Omeprazole | Omeprazole | 234 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 232 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 229 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 224 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 214 | 72 |
| Sildenafil Citrate | Sildenafil Citrate | 190 | 55 |
| Eliquis | Apixaban | 187 | 37 |
| Xarelto | Rivaroxaban | 179 | 42 |
| Famotidine | Famotidine | 159 | 70 |
| Furosemide | Furosemide | 150 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 124 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 38 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 116 | 78 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 96 | 32 |
| Simvastatin | Simvastatin | 92 | 32 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 84 | 84 |
| Carvedilol | Carvedilol | 84 | 31 |
| Folic Acid | Folic Acid | 78 | 28 |
| Montelukast Sodium | Montelukast Sodium | 77 | 31 |
| Warfarin Sodium | Warfarin Sodium | 77 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 26 |
| Entresto | Sacubitril/Valsartan | 75 | 13 |
| Trazodone Hcl | Trazodone Hcl | 73 | 28 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 69 | 20 |
| Hydrocortisone | Hydrocortisone | 69 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 26 |
| Atenolol | Atenolol | 64 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | 14 |
| Buspirone Hcl | Buspirone Hcl | 61 | 26 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 60 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 15 |
| Glipizide Er | Glipizide | 57 | 16 |
| Alendronate Sodium | Alendronate Sodium | 55 | 27 |
| Metformin Hcl Er | Metformin Hcl | 55 | 15 |
| Pregabalin | Pregabalin | 54 | 13 |
| Sertraline Hcl | Sertraline Hcl | 52 | 19 |
| Finasteride | Finasteride | 51 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 19 |
| Dutasteride | Dutasteride | 49 | 19 |
| Mirtazapine | Mirtazapine | 48 | 21 |
| Glipizide | Glipizide | 47 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 45 | 23 |
| Donepezil Hcl | Donepezil Hcl | 45 | 20 |
| Spironolactone | Spironolactone | 44 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | 30 |
| Irbesartan | Irbesartan | 42 | 11 |
| Memantine Hcl | Memantine Hcl | 40 | 16 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 36 | suppressed |
| Potassium Chloride | Potassium Chloride | 36 | 13 |
| Pradaxa | Dabigatran Etexilate Mesylate | 36 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 35 | 11 |
| Nifedipine Er | Nifedipine | 34 | 14 |
| Benzonatate | Benzonatate | 33 | 20 |
| Fenofibrate | Fenofibrate | 33 | 15 |
| Allopurinol | Allopurinol | 32 | 13 |
| Mupirocin | Mupirocin | 32 | 25 |
| Bumetanide | Bumetanide | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 31 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 28 | 11 |
| Clonidine Hcl | Clonidine Hcl | 28 | 13 |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 28 | suppressed |
| Ketoconazole | Ketoconazole | 28 | 15 |
| Lovastatin | Lovastatin | 27 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 27 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 24 |
| Glimepiride | Glimepiride | 26 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 16 |
| Alprazolam | Alprazolam | 24 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 24 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 24 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Bicalutamide | Bicalutamide | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | 11 |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Eplerenone | Eplerenone | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 18 |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Ursodiol | Ursodiol | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | 11 |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Galantamine Er | Galantamine Hbr | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $208.67 · 11 records | Amgen Inc. | Dexcom G6 Transmitter, NP Thyroid 60, OTEZLA, REPATHA, SHINGRIX, The Cologuard Plus Collection Kit | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error